Which psychological intervention do you most often recommend to patients with eosinophilic gastrointestinal tract disorders seen in your practice? Let us know by taking our poll!
Which psychological intervention do you most often recommend to patients with eosinophilic gastrointestinal tract disorders seen in your practice? Let us know by taking our poll!
Which initial noninvasive modality should be used for the diagnosis of portal vein thrombosis in patients with and without cirrhosis? Take the quiz and find out!
Which initial noninvasive modality should be used for the diagnosis of portal vein thrombosis in patients with and without cirrhosis? Take the quiz and find out!
Gastroenterology Consultant published content on various topics throughout 2019. Which topic do you want to see more of this year? Take our poll to voice your opinion!
Gastroenterology Consultant published content on various topics throughout 2019. Which topic do you want to see more of this year? Take our poll to voice your opinion!
Hutchinson-Gilford progeria syndrome affects 1 in 4 million live births. Do you know when the rare genetic syndrome was first described? Find out by answering this question.
Hutchinson-Gilford progeria syndrome affects 1 in 4 million live births. Do you know when the rare genetic syndrome was first described? Find out by answering this question.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Vonoprazan offers an effective alternative treatment to intravenous proton pump inhibitors for prevention of rebleeding among patients with high-risk peptic ulcers, researchers found.
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
Results showed that a lower fibrosis stage (F0–1) was associated with a significantly reduced risk of cirrhosis and liver-related outcomes compared to patients with advanced fibrosis (F4).
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.
The U.S. Food and Drug Administration (FDA) on October 4 approved the Cologuard Plus multitarget stool DNA test for adults ages 45 and older who are average risk for colorectal cancer.